"Psychosine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An intermediate in the biosynthesis of cerebrosides. It is formed by reaction of sphingosine with UDP-galactose and then itself reacts with fatty acid-Coenzyme A to form the cerebroside.
| Descriptor ID |
D011609
|
| MeSH Number(s) |
D02.033.100.700.700 D02.092.063.700.700 D09.400.410.420.806 D10.390.470.806 D10.570.877.360.806
|
| Concept/Terms |
Psychosine- Psychosine
- Sphingosine Galactoside
- Galactoside, Sphingosine
- Galactosylsphingosine
|
Below are MeSH descriptors whose meaning is more general than "Psychosine".
Below are MeSH descriptors whose meaning is more specific than "Psychosine".
This graph shows the total number of publications written about "Psychosine" by people in this website by year, and whether "Psychosine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Psychosine" by people in Profiles.
-
Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease. J Neurosci Res. 2016 11; 94(11):990-1006.
-
Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease. PLoS One. 2016; 11(9):e0162367.
-
Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model. Hum Mol Genet. 2015 Dec 15; 24(24):7031-48.
-
Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: potential role in neuropathology. PLoS One. 2015; 10(3):e0118771.
-
CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings. Mol Genet Metab. 2015 Feb; 114(2):233-241.
-
Substrate compositional variation with tissue/region and Gba1 mutations in mouse models--implications for Gaucher disease. PLoS One. 2013; 8(3):e57560.
-
Role of endogenous psychosine accumulation in oligodendrocyte differentiation and survival: implication for Krabbe disease. Brain Res. 2013 May 01; 1508:44-52.
-
Ex vivo and in vivo effects of isofagomine on acid ?-glucosidase variants and substrate levels in Gaucher disease. J Biol Chem. 2012 Feb 03; 287(6):4275-87.
-
Factors that affect postnatal bone growth retardation in the twitcher murine model of Krabbe disease. Biochim Biophys Acta. 2010 Jul-Aug; 1802(7-8):601-8.
-
Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet. 2010 Mar 15; 19(6):1088-97.